Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD
Ocular Therapeutix enrolled the first patient in the SOL-X long-term extension trial for AXPAXLI in wet AMD. The 36-month open-label study allows patients who completed the SOL-1 or SOL-R trials to receive an additional three years of treatment every 24 weeks.
Key figures
- Drug Name
- AXPAXLI (OTX-TKI)
- Phase Of Trial
- Phase 3 Extension
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.